[18F]AV-1451 tau positron emission tomography in progressive supranuclear palsy

Movement Disorders

Volumn 32, Issue 1, 2017, Pages 124-133

  Whitwell, Jennifer L ^a   Lowe, Val J ^a   Tosakulwong, Nirubol ^a   Weigand, Stephen D ^a   Senjem, Matthew L ^a   Schwarz, Christopher G ^a   Spychalla, Anthony J ^a   Petersen, Ronald C ^a   Jack, Clifford R ^a   Josephs, Keith A ^a  

^a MAYO CLINIC   (United States)

Author keywords

Alzheimer's dementia; positron emission tomography; progressive supranuclear palsy; Tau

Indexed keywords

FLORTAUCIPIR F 18; TAU PROTEIN; 7-(6-FLUOROPYRIDIN-3-YL)-5H-PYRIDO(4,3-B)INDOLE; CARBOLINE DERIVATIVE;

ADULT; AGED; ALZHEIMER DISEASE; ARTICLE; BRAIN REGION; CAUDATE NUCLEUS; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; DENTATE NUCLEUS; DISEASE SEVERITY; FEMALE; FRONTAL CORTEX; GLOBUS PALLIDUS; HUMAN; MALE; MESENCEPHALON; NEUROIMAGING; PET-CT SCANNER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSIVE SUPRANUCLEAR PALSY; PROGRESSIVE SUPRANUCLEAR PALSY RATING SCALE; RATING SCALE; THALAMUS; BRAIN; COMPARATIVE STUDY; DIAGNOSTIC IMAGING; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROCEDURES; SEVERITY OF ILLNESS INDEX;

AGED; ALZHEIMER DISEASE; BRAIN; CARBOLINES; FEMALE; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; SEVERITY OF ILLNESS INDEX; SUPRANUCLEAR PALSY, PROGRESSIVE; TAU PROTEINS;

EID: 84999749714     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26834     Document Type: Article

References (37)

1. Hauw JJ, Daniel SE, Dickson D, et al. Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology 1994;44(11):2015–2019.
2. Dickson DW, Hauw JJ, Agid Y, Litvan I. Progressive Supranuclear palsy and corticobasal degeneration. In: Dickson D, Weller RO, eds. Neurodegeneration: The Molecular Pathology of Dementia and Movement Disorders. 2nd ed. Chichester, UK: Wiley-Blackwell, 2011, 135–155.
3. Litvan I, Agid Y, Calne D, et al. Clinical research criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome): report of the NINDS-SPSP International Workshop. Neurology 1996;47(1):1–9.
4. Steele JC, Richardson JC, Olszewski J. Progressive supranuclear palsy. A heterogeneous degeneration involving the brain stem, basal ganglia and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia and dementia. Arch Neurol 1964;10:333–359.
5. Chien DT, Bahri S, Szardenings AK, et al. Early clinical PET imaging results with the novel PHF-tau radioligand [F-18]-T807. J Alzheimers Dis 2013;34(2):457–468.
6. Xia CF, Arteaga J, Chen G, et al. [(18)F]T807, a novel tau positron emission tomography imaging agent for Alzheimer's disease. Alzheimers Dement 2013;9(6):666–676.
7. Cho H, Choi JY, Hwang MS, et al. Tau PET in Alzheimer disease and mild cognitive impairment. Neurology 2016. doi: 10.1212/WNL.0000000000002892. Epub 2016 Jun 29.
8. Johnson KA, Schultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging and early Alzheimer disease. Ann Neurol 2016;79(1):110–119.
9. Williams DR, Holton JL, Strand K, Revesz T, Lees AJ. Pure akinesia with gait freezing: a third clinical phenotype of progressive supranuclear palsy. Mov Disord 2007;22(15):2235–2241.
10. Williams DR, de Silva R, Paviour DC, et al. Characteristics of two distinct clinical phenotypes in pathologically proven progressive supranuclear palsy: Richardson's syndrome and PSP-parkinsonism. Brain 2005;128(Pt 6):1247–1258.
11. Golbe LI, Ohman-Strickland PA. A clinical rating scale for progressive supranuclear palsy. Brain 2007;130(Pt 6):1552–1565.
12. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc 2005;53(4):695–699.
13. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011;7(3):263–269.
14. Folstein MF, Folstein SE, McHugh PR. “Mini-mental state”. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12(3):189–198.
15. Meltzer CC, Kinahan PE, Greer PJ, et al. Comparative evaluation of MR-based partial-volume correction schemes for PET. J Nucl Med 1999;40(12):2053–2065.
16. Tzourio-Mazoyer N, Landeau B, Papathanassiou D, et al. Automated anatomical labeling of activations in SPM using a macroscopic anatomical parcellation of the MNI MRI single-subject brain. NeuroImage 2002;15(1):273–289.
17. Vemuri P, Whitwell JL, Kantarci K, et al. Antemortem MRI based STructural Abnormality iNDex (STAND)-scores correlate with postmortem Braak neurofibrillary tangle stage. NeuroImage 2008;42(2):559–567.
18. Ashburner J, Friston KJ. Unified segmentation. NeuroImage 2005;26(3):839–851.
19. Rothman KJ. No adjustments are needed for multiple comparisons. Epidemiology 1990;1(1):43–46.
20. Hammes J, Bischof GN, Giehl K, et al. Elevated in vivo [18F]-AV-1451 uptake in a patient with progressive supranuclear palsy. Mov Disord 2016. doi: 10.1002/mds.26727. [Epub ahead of print].
21. Lowe VJ, Curran G, Fang P, et al. An autoradiographic evaluation of AV-1451 tau PET in dementia. Acta Neuropathol Commun 2016;4(1):58.
22. Whitwell JL, Avula R, Master A, et al. Disrupted thalamocortical connectivity in PSP: a resting-state fMRI, DTI, and VBM study. Parkinsonism Relat Disord 2011;17(8):599–605.
23. Agosta F, Galantucci S, Svetel M, et al. Clinical, cognitive, and behavioural correlates of white matter damage in progressive supranuclear palsy. J Neurol 2014;261(5):913–924.
24. Whitwell JL, Master AV, Avula R, et al. Clinical correlates of white matter tract degeneration in progressive supranuclear palsy. Arch Neurol 2011;68(6):753–760.
25. Schofield EC, Hodges JR, Macdonald V, Cordato NJ, Kril JJ, Halliday GM. Cortical atrophy differentiates Richardson's syndrome from the parkinsonian form of progressive supranuclear palsy. Mov Disord 2011;26(2):256–263.
26. Sander K, Lashley T, Gami P, et al. Characterization of tau positron emission tomography tracer [F]AV-1451 binding to postmortem tissue in Alzheimer's disease, primary tauopathies, and other dementias. Alzheimers Dement 2016. Feb 15. pii: S1552-5260(16)00033-9. doi: 10.1016/j.jalz.2016.01.003. [Epub ahead of print].
27. Marquie M, Normandin MD, Vanderburg CR, et al. Validating novel tau positron emission tomography tracer [F-18]-AV-1451 (T807) on postmortem brain tissue. Annals of neurology 2015;78(5):787–800.
28. Smith R, Puschmann A, Scholl M, et al. 18F-AV-1451 tau PET imaging correlates strongly with tau neuropathology in MAPT mutation carriers. Brain 2016.
29. Scholl M, Lockhart SN, Schonhaut DR, et al. PET imaging of tau deposition in the aging human brain. Neuron 2016;89(5):971–982.
30. Murray ME, Graff-Radford NR, Ross OA, Petersen RC, Duara R, Dickson DW. Neuropathologically defined subtypes of Alzheimer's disease with distinct clinical characteristics: a retrospective study. Lancet Neurol 2011;10(9):785–796.
31. Whitwell JL, Dickson DW, Murray ME, et al. Neuroimaging correlates of pathologically defined subtypes of Alzheimer's disease: a case-control study. Lancet Neurol 2012;11(10):868–877.
32. Josephs KA, Petersen RC, Knopman DS, et al. Clinicopathologic analysis of frontotemporal and corticobasal degenerations and PSP. Neurology 2006;66(1):41–48.
33. Respondek G, Roeber S, Kretzschmar H, et al. Accuracy of the National Institute for Neurological Disorders and Stroke/Society for Progressive Supranuclear Palsy and neuroprotection and natural history in Parkinson plus syndromes criteria for the diagnosis of progressive supranuclear palsy. Mov Disord 2013;28(4):504–509.
34. Josephs KA, Whitwell J, Tosakulwong N, Weigand SD, Petersen RC, Jack CR, Lowe V. AV-1451 tau-PET in progressive supranuclear palsy variants. 10th Human Amyloid Imaging Conference 2016;63.Abstract no.PE58.
35. Hansen AK, Knudsen K, Lillethorup TP, et al. In vivo imaging of neuromelanin in Parkinson's disease using 18F-AV-1451 PET. Brain 2016;139(Pt 7):2039–2049.
36. Dani M, Brooks DJ, Edison P. Tau imaging in neurodegenerative diseases. Eur J Nucl Med Mol Imaging 2016;43(6):1139–1150.
37. Maruyama M, Shimada H, Suhara T, et al. Imaging of tau pathology in a tauopathy mouse model and in Alzheimer patients compared to normal controls. Neuron 2013;79(6):1094–1108.